

## MIT Open Access Articles

*Stress from Nucleotide Depletion Activates the  
Transcriptional Regulator HEXIM1 to Suppress Melanoma*

The MIT Faculty has made this article openly available. **Please share**  
how this access benefits you. Your story matters.

**Citation:** Tan, Justin L. et al. "Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma." *Molecular Cell* 62, 1 (April 2016): 34–46 © 2016 Elsevier Inc

**As Published:** <http://dx.doi.org/10.1016/J.MOLCEL.2016.03.013>

**Publisher:** Elsevier

**Persistent URL:** <http://hdl.handle.net/1721.1/116990>

**Version:** Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

**Terms of use:** Creative Commons Attribution-NonCommercial-NoDerivs License





Published in final edited form as:

*Mol Cell*. 2016 April 7; 62(1): 34–46. doi:10.1016/j.molcel.2016.03.013.

## Stress from nucleotide depletion activates the transcriptional regulator HEXIM1 to suppress melanoma

Justin L. Tan<sup>1,2</sup>, Rachel D. Fogley<sup>1,2</sup>, Ryan A. Flynn<sup>3</sup>, Julien Ablain<sup>1,2</sup>, Song Yang<sup>1,2</sup>,  
Violaine Saint-André<sup>4</sup>, Zi Peng Fan<sup>4</sup>, Brian T. Do<sup>3</sup>, Alvaro C. Laga<sup>5</sup>, Koh Fujinaga<sup>6</sup>, Cristina  
Santoriello<sup>1,2</sup>, Celeste B. Greer<sup>7</sup>, Yoon Jung Kim<sup>8</sup>, John G. Clohessy<sup>9,10</sup>, Anne Bothmer<sup>9</sup>,  
Nicole Pandell<sup>10</sup>, Serine Avagyan<sup>1,2</sup>, John E. Brogie<sup>11</sup>, Ellen van Rooijen<sup>1,2</sup>, Elliott J.  
Hagedorn<sup>1,2</sup>, Ng Shyh-Chang<sup>12</sup>, Richard M. White<sup>13</sup>, David H. Price<sup>11</sup>, Pier Paolo Pandolfi<sup>9</sup>,  
B. Matija Peterlin<sup>6</sup>, Yi Zhou<sup>1,2</sup>, Tae Hoon Kim<sup>8</sup>, John M. Asara<sup>14</sup>, Howard Y. Chang<sup>3</sup>, Richard  
A. Young<sup>4</sup>, and Leonard I. Zon<sup>1,2,\*</sup>

<sup>1</sup>Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/  
Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School,  
Boston, MA 02115, USA.

<sup>2</sup>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA  
02138, USA.

<sup>3</sup>Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA  
94305, USA.

<sup>4</sup>Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute  
of Technology, Cambridge, MA 02142, USA.

<sup>5</sup>Department of Pathology, Brigham & Women's Hospital, Boston, MA 02215, USA.

<sup>6</sup>Departments of Medicine, Microbiology and Immunology, Rosalind Russell Medical Research  
Center, University of California, San Francisco, CA 94143, USA.

<sup>7</sup>Department of Pharmacology, Yale University, School of Medicine, New Haven, CT 06520, USA.

<sup>8</sup>Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080,  
USA.

\*Corresponding Author: Leonard I. Zon, Boston Children's Hospital / HHMI, Karp Research Building, Room 7211, 300 Longwood  
Ave, Boston, MA 02115, 617-919-2069, zon@enders.tch.harvard.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our  
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of  
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be  
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

### Author Contributions:

Conceptualization, J.L.T. and L.I.Z.; Supervision, J.L.T., R.M.W., D.H.P., P.P.P., B.M.P., T.H.K., J.M.A., H.Y.C., R.A.Y. and L.I.Z.;  
Funding Acquisition & Resources, L.I.Z., D.H.P., P.P.P., B.M.P., Y.Z., T.H.K., J.M.A., H.Y.C. and R.A.Y.; Writing – Original Draft,  
J.L.T.; Writing – Review & Editing, J.L.T. and L.I.Z.; Methodology, J.L.T. and L.I.Z.; Investigation, J.L.T., R.D.F., R.A.F., J.A., S.Y.,  
V.S., Z.P.F., B.T.D., A.C.L., K.F., C.S., C.B.G., Y.J.K., J.G.C., A.B., N.P., S.A., J.E.B., E.v.R., E.J.H. and N.S.; Formal Analysis,  
J.L.T., R.A.Y., S.Y. and C.B.G.

### eTOC Blurb:

Tan et al. demonstrate that the gene *HEXIM1* is a tumor suppressor in melanoma that responds to nucleotide stress by inhibiting  
transcription elongation of tumorigenic genes and stabilizing mRNA transcripts of other tumor suppressor genes. These results suggest  
an important paradigm for targeting melanoma through metabolic stress-induced transcription regulation.

<sup>9</sup>Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

<sup>10</sup>Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

<sup>11</sup>Department of Biochemistry, University of Iowa, Iowa City, IO 52242, USA.

<sup>12</sup>Genome Institute of Singapore, 60 Biopolis St, 138672, Singapore.


<sup>13</sup>Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College, New York, NY 10065, USA.

<sup>14</sup>Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

## Summary

Studying cancer metabolism gives insight into tumorigenic survival mechanisms and susceptibilities. In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress. *HEXIM1* expression is low in melanoma. Its overexpression in a zebrafish melanoma model suppresses cancer formation while its inactivation accelerates tumor onset *in vivo*. Knockdown of *HEXIM1* rescues zebrafish neural crest defects and human melanoma proliferation defects that arise from nucleotide depletion. Under nucleotide stress, HEXIM1 is induced to form an inhibitory complex with P-TEFb, the kinase that initiates transcription elongation, to inhibit elongation at tumorigenic genes. The resulting alteration in gene expression also causes anti-tumorigenic RNAs to bind to and be stabilized by HEXIM1. HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression. Our study reveals an important role for HEXIM1 in coupling nucleotide metabolism with transcriptional regulation in melanoma.

## Graphical Abstract



## Introduction

The ability of cancer cells to alter metabolism to enhance survival and adapt to the microenvironment has been studied to understand tumorigenic mechanisms that can be therapeutically targeted. Nucleotide metabolism is dysregulated in cancer. Imbalances in nucleotide pools alter mutation rates (Meuth, 1989; Weinberg et al., 1981). Dysregulation of nucleotide biosynthesis precursors glycine and glutamine in tumorigenesis invoke changes in nucleotide metabolism (Liu et al., 2012; Zhang et al., 2012). Genetic mutations with altered nucleotide metabolism cause chromosomal instability (Chabosseau et al., 2011; Chang et al., 2013). Our previous work found that inhibition of *de novo* pyrimidine biosynthesis enzyme dihydro-orotate dehydrogenase (DHODH), by drug leflunomide (lefl), ablates zebrafish neural crest and suppresses melanoma through an unclear transcription elongation mechanism (White et al., 2011).

Control of the elongation phase of RNA polymerase II (RNA Pol II) transcription regulates gene expression during differentiation (Guo and Price, 2013). After initiation, RNA Pol II becomes paused at the promoter by negative transcription elongation factors such as DSIF and NELF (Muse et al., 2007; Rahl et al., 2010). Release of these promoter proximal paused polymerases into productive elongation requires positive transcription elongation factor b (P-TEFb) (Marshall et al., 1996). P-TEFb, comprising cyclin-dependent kinase 9 (CDK9) and either cyclin T1 or T2 (CCNT1/2), phosphorylates RNA Pol II (Marshall et al., 1996), DSIF (Yamada et al., 2006) and NELF (Fujinaga et al., 2004). This releases NELF from the elongation complex and converts DSIF into a positive factor (Fujinaga et al., 2004; Yamada et al., 2006), resulting in productive elongation (Rahl et al., 2010).

The 7SK snRNP critically regulates transcription elongation by sequestering and inactivating P-TEFb (Peterlin et al., 2012). Negative regulation of P-TEFb by HEXIM1 in the 7SK snRNP is essential for regulating gene expression. HEXIM1 binds to 7SK RNA and

sequesters P-TEFb in an inactive state (Yik et al., 2003). 7SK snRNP components MEPCE (bcdin3) (Jeronimo et al., 2007) and LARP7 (He et al., 2008) maintain 7SK stability. Regulated release of P-TEFb from the 7SK snRNP is important for rapid gene induction for metazoan development. 7SK snRNP disruption leads to developmental abnormalities in zebrafish (Barboric et al., 2009) and humans (Alazami et al., 2012).

To determine how nucleotide metabolism affects transcription in tumors, we examined the relevance of negative regulators of transcription elongation in cancer and found that *HEXIM1* features significantly in melanoma. Our analysis revealed that *HEXIM1* mRNA and protein levels are low in melanoma. *In vivo* studies demonstrate that *HEXIM1* functions as a melanoma suppressor: its overexpression suppresses tumor onset, while its inactivation accelerates tumorigenesis. Pyrimidine nucleotide depletion induces SP1-mediated *HEXIM1* upregulation to suppress melanocyte and neural crest formation *in vivo*. Under nucleotide stress, *HEXIM1* forms an inhibitory complex with P-TEFb, inhibiting productive elongation at neural crest-associated and tumorigenic genes. The alteration in gene expression causes anti-tumorigenic transcripts to bind to and become stabilized by *HEXIM1*. *HEXIM1* induction by nucleotide stress facilitates a gene expression switch, inhibiting tumorigenic gene transcription while favoring anti-tumorigenic gene transcription. The ability of *HEXIM1* to couple nucleotide stress with an anti-melanoma transcriptional response is an important mechanism in tumor metabolism.

## Results

### HEXIM1 expression is low in melanoma

We evaluated the role of candidate transcription elongation regulators in Oncomine (Rhodes et al., 2004) and only *HEXIM1* expression was significantly altered in melanoma (data not shown). We analyzed two human melanoma microarray datasets for *HEXIM1* expression (Lin et al., 2008; Talantov et al., 2005). Talantov *et al.* studied gene expression from primary melanoma and benign skin nevi, while Lin *et al.* examined gene expression in melanoma short-term cultures and cell lines. *HEXIM1* is downregulated by at least 2-fold in 78% of nevi compared to normal skin controls (Figures 1A and S1A). Comparing melanoma and skin, *HEXIM1* is downregulated in 100% of melanoma cases by at least 2-fold (Figures 1A and S1A). In short-term cultures and cell lines vs. normal melanocyte lines, 44% of melanoma cases have *HEXIM1* downregulated by at least 2-fold (Figures 1B and S1A). Other 7SK snRNP members were not significantly downregulated (Figure S1B). *HEXIM1* is likely downregulated in melanoma.

To assess *HEXIM1* protein levels, we performed immunohistochemistry on human melanoma tissue microarrays. We scored them by the H-score method on a scale of 0 to 300 (McClelland et al., 1990). 66% of nevi and 72% of human melanoma samples showed low H-scores of < 100, corresponding to low *HEXIM1* protein levels (Figures 1C and S1C). 6% of nevi and 13% of melanoma showed high *HEXIM1* levels with H-scores of > 200 (Figures S1C and S1D). 100% of normal epidermal samples scored high for *HEXIM1* expression, with 94% of samples possessing H-scores of > 200 (Figures S1C and S1D). As melanoma is derived from melanocytes, we examined normal epidermal sections co-stained for *HEXIM1* and MART1, a melanocyte specific cell surface antigen (Kawakami et al., 1994).

Melanocytes co-express high levels of both MART1 and HEXIM1, meaning that HEXIM1 protein levels are high in normal melanocytes compared to nevi and melanoma (Figure S1E). These results suggest that HEXIM1 protein is downregulated in melanoma.

There are no significant mutations in the *HEXIM1* gene across tumor databases (data not shown), suggesting that in melanoma, epigenetic silencing might cause *HEXIM1* downregulation. We examined DNA methylation of the *HEXIM1* locus using MethHC (Huang et al., 2015) to analyze melanoma methylation data from The Cancer Genome Atlas (TCGA). The *HEXIM1* promoter is hypermethylated in tumor samples, suggesting that hypermethylation downregulates *HEXIM1* (Figure 1D). To functionally test if the *HEXIM1* promoter is methylated in melanoma, we treated the human A375 melanoma cell line with 5-azacytidine, a DNA methyltransferase (DNMT) inhibitor which removes methylation on DNA (Creusot et al., 1982). We observed a dose-dependent upregulation of *HEXIM1* transcripts (Figure 1E) and reduced cell viability (Figure 1F) with DNMT inhibition. Together, the expression patterns and epigenetic silencing by DNA methylation suggest that *HEXIM1* is a tumor suppressor that is downregulated in melanoma.

### ***HEXIM1* overexpression suppresses melanoma onset while its inactivation accelerates melanoma *in vivo***

To investigate the *in vivo* action of HEXIM1 on melanoma, we overexpressed human *HEXIM1* and zebrafish *hexim1* in the MiniCoopR zebrafish assay system (Ceol et al., 2011). Compared to the *EGFP* background control and the *SETDB1* positive control, which accelerates tumor onset, both human *HEXIM1* and fish *hexim1* suppress melanoma onset (Figures 2A and 2B). 80% of *HEXIM1/hexim1* fish remain tumor-free at the 25-week endpoint, while 30% of *EGFP* and 10% of *SETDB1* fish are tumor-free.

We investigated if HEXIM1 suppression of tumorigenesis is dependent on its P-TEFb sequestration function. HEXIM1/P-TEFb interaction is modulated by mutating HEXIM1 amino acid residues at S268, T270, T276 and S278, located at the P-TEFb binding domain (Contreras et al., 2007). Mutating these sites to aspartic acid generates *HEXIM1-4D*, which ablates P-TEFb binding. Mutating these sites to alanine generates *HEXIM1-4A*, which efficiently sequesters P-TEFb. Overexpressing *HEXIM1-4A* suppresses tumors to a similar extent as *HEXIM1* and *hexim1* (Figure 2C). Overexpressing *HEXIM1-4D* did not suppress tumors and tumorigenesis continued at a similar rate to *EGFP* (Figure 2C). We validated MiniCoopR transgenic construct expression by sequencing and western blots (Figures S2A, S2B and S2C).

We investigated the effects of *HEXIM1* overexpression in melanocytes during development. We outcrossed *HEXIM1*, *HEXIM1-4A* and *-4D* MiniCoopR transgenic fish to the *Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>* parental strain and examined melanocytes at 2 days post fertilization (dpf), using a Tu wildtype strain incross as control (Figure S2D). The outcrosses for the *HEXIM1* and *HEXIM1-4D* strains produced offspring with an embryonic decrease in melanocytes, similar to DHODH inhibition effects (White et al., 2011). This melanocyte reduction did not occur for the *EGFP* or *HEXIM1-4A* strains. These studies show that the capacity of HEXIM1 to sequester P-TEFb is required for its function in tumor suppression and development.

To analyze the effect of HEXIM1 inactivation *in vivo*, we employed a CRISPR/Cas9 knockout of *hexim1* in our zebrafish melanoma model. Under control of the MiniCoopR vector, we expressed *hexim1* and *p53* control guide RNAs, and Cas9 in a melanocyte-specific fashion (Ablain et al., 2015) to examine tumor onset. Since the *Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>* fish have non-functional *p53*, the *p53* CRISPR controls for random targeting events. Mutation of the *hexim1* gene was confirmed by a T7E1 enzymatic genotyping assay and western blot showed lower hexim1 protein levels (Figures S2E and S2F). Reduced hexim1 expression due to heterozygous inactivation resulted in accelerated tumor onset compared to the *p53* control (Figure 2D), consistent with HEXIM1 functioning as a tumor suppressor.

We examined the tumor suppressive ability of HEXIM1 in a mouse xenograft model with a Tet-On *HEXIM1*-inducible A375 melanoma cell line (A375-HEXIM1). HEXIM1 induction with a doxycycline diet significantly reduced tumor growth rates compared to uninduced mice (Figure 2E and S2G), complementing our fish data that HEXIM1 is a melanoma suppressor.

### **Knockdown of *HEXIM1* rescues neural crest and melanoma phenotypes associated with nucleotide stress**

DHODH inhibition by *lef* ablates *crestin* (neural crest marker) and *mitfa* (master regulator of melanocyte fate) gene expression in developing zebrafish embryos (White et al., 2011). *Hexim1* morpholino knockdown partially rescues *crestin* and *mitfa* expression in *lef*-treated zebrafish embryos (Figure 3A). Melanocytes are partially rescued (Figures 3B and 3C). Overexpressing human HEXIM1, via mRNA injection, with zebrafish *hexim1* knockdown ablated the rescue. We validated hexim1 protein knockdown via western blot (Figure S3A). *Hexim1* is ubiquitously expressed in early zebrafish development (Figures S3B, S3C and S3D). Knockdown of 7SK snRNP members *larp7* and *mepce* recapitulated the rescue of melanocytic gene expression and melanocytes seen in *hexim1* knockdown (Figures S3E and S3F). We observed melanocyte reduction in our HEXIM1 overexpressing zebrafish embryos (Figure S2D) similar to the *lef* embryonic phenotype. However, this is only a partial phenocopy of *lef* since *crestin* expression is unchanged (data not shown), possibly because *HEXIM1* is specifically overexpressed in melanocytes under the *mitfa* promoter and the early neural crest cells affected by *lef* are still present in the transgenic embryos. *Hexim1* plays a role in neural crest *in vivo* effects caused by nucleotide stress.

DHODH inhibition causes growth arrest in the human A375 melanoma cell line (White et al., 2011). We performed pooled siRNA knockdown of *HEXIM1* on A375 cells treated with A771726 and showed a partial rescue of the growth arrest phenotype (Figure 3D). A combined *HEXIM1* and *HEXIM2* knockdown marginally improved rescue while applying a non-targeting siRNA pool or *GAPDH* knockdown did not rescue (Figure 3D). Knockdowns were validated by RT-PCR (Figure S3G). These results suggest that HEXIM1 plays an important role in the transcriptional response to nucleotide stress in the neural crest lineage and melanoma.

### HEXIM1 is upregulated in response to nucleotide stress in melanoma

Metabolite profiling of A375 cells with metabolized lef, A771726, revealed that that pyrimidine biosynthesis and RNA transcription associated metabolites are primarily dysregulated (Figure S4A, Tables S1A and S1C). Metabolites upstream of DHODH are upregulated while metabolites downstream of DHODH are downregulated (Figures S4B and S4C). Changes are limited to pyrimidine intermediates before 48 hrs, after which secondary effects, such as purine metabolite changes, are observed (Figures S4A and S4C, Tables S1A and S1B). This highlights the specificity of DHODH inhibitors to pyrimidine biosynthesis.

To examine the effect of pyrimidine stress on *HEXIM1* expression, zebrafish embryos and human A375 cells were treated with lef and A771726 respectively. *HEXIM1* is upregulated with drug treatment in both systems in a dose-dependent manner by mRNA and protein levels (Figures 4A, 4B, 4C and 4D). We tested A771726 in our A375 *HEXIM1*-luciferase reporter line (Liu et al., 2014). A771726 increased *HEXIM1* expression over time, similar to positive control hexamethylene bis-acetamide (HMBA) that upregulates *HEXIM1* (Figure 4E). *HEXIM1* is upregulated after 48 hrs of drug treatment (Figure 4F) when pyrimidine nucleotides are significantly depleted (Figure S4C), and when growth arrest becomes significant (Figure 4G). Increased *HEXIM1* expression induced by nucleotide stress can be rescued by adding pyrimidine nucleotides to drug-treated cells (Figure 4H). Adding nucleotides alone does not alter *HEXIM1* expression (Figure 4H), suggesting that the role of *HEXIM1* in transcriptional regulation is prominent in times of starvation and not nucleotide excess. Nucleotide starvation activates *HEXIM1* with a corresponding decrease in cell proliferation.

### HEXIM1 is upregulated by SP1 under nucleotide stress

We asked which transcription factor is responsible for *HEXIM1* nucleotide stress upregulation by examining the ENCODE transcription factor ChIP-seq database (ENCODE Project Consortium, 2012) and selecting eight candidate transcription factors that significantly bind the *HEXIM1* promoter. We screened these factors by siRNA knockdown to determine which one promotes *HEXIM1* upregulation under nucleotide stress (Figure S5A). Knockdown was validated by RT-PCR (Figure S5B). *SP1* knockdown significantly blocked *HEXIM1* upregulation by A771726 treatment (Figures 5A and S5A). *SP1* is a stress response factor (Ryu et al., 2003) and its knockdown partially rescues lef-induced growth arrest similar to *HEXIM1* knockdown (Figure 5B). The *HEXIM1* minimal promoter element used in the luciferase reporter assay in Figure 4E contains an *SP1* binding element (Liu et al., 2014). ChIP-seq experiments demonstrate that *SP1* binding is increased at many loci under nucleotide stress, where some genes are activated while others are repressed by RNA-seq (data not shown). The *HEXIM1* promoter is one region where *SP1* binding is increased (Figure 5C) with an associated increase in *HEXIM1* expression. These data establish a role for *SP1* in the upregulation of *HEXIM1* expression under nucleotide stress conditions.

### HEXIM1 induction sequesters P-TEFb away from gene promoters

We investigated if *HEXIM1* chromatin occupancy is affected by nucleotide stress by performing ChIP-seq for CDK9 and *HEXIM1* in A375 cells treated with A771726 for 48 hrs. We chose the 48 hr time point since *HEXIM1* protein levels are significantly

upregulated (Figure 4F) with no induction of apoptosis (data not shown). It takes 24 hrs for lef to downregulate pyrimidines (Figure S4C), after which HEXIM1 is induced. RNA Pol II ChIP-seq and meta-gene analysis were performed on the same batch of cells to show that drug treatment did not affect immunoprecipitation efficiency (Figure S6A).

Meta-gene analysis demonstrates that CDK9 and HEXIM1 are localized at gene promoters (Figures 6A and 6B). ChIP-seq region plots for CDK9 and HEXIM1 binding throughout the genome, based on either CDK9 or HEXIM1 binding regions in the DMSO control, show co-binding of HEXIM1 with CDK9 at the same regions (Figure 6C). We confirmed this co-binding by performing ChIP-reChIP for HEXIM1 and CDK9. ChIP-reChIP region and meta-gene plots demonstrate that HEXIM1 and CDK9 indeed bind at identical chromatin regions (Figures S6B and S6C).

A771726 treatment reduces both CDK9 and HEXIM1 occupancy at the promoters (Figures 6A and 6B). This reduction could be due to increased HEXIM1 sequestration of P-TEFb, where coimmunoprecipitation of HEXIM1 demonstrates that more CDK9 is being incorporated into the 7SK snRNP inhibitory complex with drug (Figure S6D). HEXIM1 binding to P-TEFb is crucial for its *in vivo* tumor suppression activity and developmental effects (Figures 1H and S2D), which could account for the anti-proliferative effect that A771726 has on melanoma. These data suggest that HEXIM1 poises P-TEFb at gene promoters for a rapid release to the transcriptional machinery when required. Upon nucleotide stress, HEXIM1 is induced to sequester PTEFb to decrease productive elongation.

### HEXIM1 induction reduces productive elongation at neural crest and tumorigenic genes

To examine the transcriptional effects of HEXIM1 sequestration of P-TEFb under nucleotide stress, we performed Global Run-On sequencing (GRO-seq) on A375 cells treated with lef or A771726 at the same time point as our ChIP-seq experiments. Genes that were considered expressed in the DMSO condition, with a traveling ratio (TR) cutoff of less than 7.5 (White et al., 2011), were used in the GRO-seq analysis for DMSO, lef and A771726 conditions. TR is a measure of RNA Pol II transcription along a gene in which read density at the promoter is divided by read density along the gene body (Rahl et al., 2010; Zeitlinger et al., 2007). A higher TR corresponds to a decrease in productive elongation. RNA Pol II occupancy at the promoters and gene bodies is plotted for short-listed gene loci in all three conditions (Figure S6E). Overall TRs calculated from Figure S6E show a significant increase in TR for both lef and A771726 treatment (Figure 6D). Gene meta-analysis shows that RNA Pol II density is lower in the gene body with nucleotide stress (Figure 6E). RNA Pol II promoter density remains largely unchanged (Figure 6E), indicating that productive elongation is reduced with little effect on Pol II promoter proximal pausing. Example tracks of unaffected housekeeping gene  $\beta$ -Actin (*ACTB*) and affected melanoma-associated transcription factor *HMGA2* (Raskin et al., 2013) are shown (Figure S6F). GRO-seq suggests that nucleotide stress reduces productive elongation in melanoma.

To assess HEXIM1's role in the reduction of productive elongation, we examined Serine-2 phosphorylation (Ser2p) of the RNA Pol II C-terminal domain in A375 cells treated with A771726 and with *HEXIM1* pooled knockdown. The transition into productive elongation

mediated by P-TEFb leads to increased Ser2p (Adelman and Lis, 2012). In cells with non-targeting siRNA, Ser2p is decreased by 40% with increased HEXIM1 levels (Figure S6G). We expect this decrease in Ser2p since GRO-seq demonstrates a reduction in productive elongation at actively transcribed genes. Reduced Ser2p is rescued by *HEXIM1* knockdown (Figure S6G). Nucleotide stress also causes a moderate transcription initiation defect, evident from the decrease in initiation marker Serine-5 phosphorylation (Ser5p) only partially rescued by *HEXIM1* knockdown (Figure S6G). We induced *HEXIM1* in the A375-*HEXIM1* cell line and observed a 40% decrease in Ser2p similar to A771726 treatment of endogenous A375 cells (Figure S6H). Ser5p is not significantly affected with *HEXIM1* overexpression (Figure S6H). RNA-seq on this *HEXIM1* overexpressing line showed a trend of gene expression downregulation (Figure S6I). Gene expression was quantified by number of fragments per kilobase of transcript per million mapped reads (FPKM), with a cut-off of FPKM > 1 for expressed genes. We curated genes lists for significantly downregulated genes (defined as having an FPKM value of > 1 in the uninduced condition, with a corresponding decrease in FPKM upon *HEXIM1* induction by > 1.5 fold) in the *HEXIM1* overexpression RNA-seq (Table S2A) and genes with significant reduction in elongation (fold change in TR > 1.3, drug vs. DMSO) in the GRO-seq experiments (Figure 6F). We observed 692 genes that have decreased expression and elongation (Figure S6J). These results suggest that nucleotide stress induces HEXIM1 to reduce Ser2p and RNA Pol II mediated transcription elongation.

To examine how nucleotide stress-induced elongation inhibition suppresses melanoma, we performed Ingenuity Pathway Analysis (IPA) on the overlapping 2,003 GRO-seq genes with significant reduction in elongation (Figure 6F, Table S2B). Genes involved in gene expression, cell proliferation and cell death are enriched (Table S2C). We also performed IPA on a 137-gene list, obtained from overlapping the GRO-seq list with our previously published RNA Pol II ChIP-seq list (Figure S6K, Table S2D), which showed enrichment in cell cycle and proliferation pathways (Table S2E). A list of 368 neural crest associated genes was generated based on literature (Table S2F) and compared to GRO-seq elongation-inhibited genes in Figure 6F. 33 neural crest associated genes, including known melanoma oncogenes, have significantly reduced elongation by GRO-seq (Table S2G). Through transcription factor motif analysis, MYC target genes were preferentially elongation-inhibited (Figure S6L), as reported in our previous study (White et al., 2011). These data suggest that nucleotide stress induces HEXIM1 to suppress melanoma by reducing productive elongation at genes associated with melanoma progression.

### **HEXIM1 binds anti-tumorigenic transcripts under nucleotide stress**

To survey global HEXIM1 RNA targets and determine if nucleotide stress causes changes in these RNA interactions, we performed FAST-iCLIP (Flynn et al., 2015) on HEXIM1 with A771726 treatment in A375 cells (Figure S7A). The proportion of 7SK bound to HEXIM1 did not change significantly with drug (data not shown). We detected significant changes in mRNA transcripts bound to HEXIM1 (Figure 7A). Transcripts from 2012 genes were prominently bound by HEXIM1 at steady state. Upon nucleotide stress induction, 1063 transcripts were no longer detected while 875 new gene transcripts were bound (Figure 7A). We observed 232 transcripts with increased binding, while 299 transcripts had decreased

binding (Figure 7A). Example transcripts of *CDKN1A* and *PTEN* are increasingly bound by HEXIM1 under nucleotide stress, while there is no change for *CCNT2* transcripts (Figure 7B). HEXIM1 RNA binding changes dynamically on specific gene transcripts although others remain unaffected.

To discern the biological consequence of altered HEXIM1 binding of mRNAs, we performed RNA-seq on A375 cells at various A771726-treatment time points as well as a DMSO-control 72 hr treatment to compare the changes in gene expression with the transcripts differentially bound by iCLIP. We found a positive correlation between transcripts that are upregulated by nucleotide stress in RNA-seq and transcripts bound more strongly by HEXIM1 under nucleotide stress (Figure S7B and Table S3). When comparing these transcripts to a list of GRO-seq genes that had increased transcriptional activity (TR fold change < 0.7) upon nucleotide stress, 116 genes, such as *CDKN1A*, were transcriptionally activated and increasingly bound by HEXIM1 (Figure S7C). Knockdown of *HEXIM1* and *HEXIM2* partially rescued the increased expression of these transcripts that were increasingly bound by HEXIM1 under nucleotide stress, such as *CDKN1A* and *PTEN* (Figure 7C). We detected genes such as *CCNT2* that were bound by HEXIM1 and did not show any significant binding change under nucleotide stress (Figure 7B). These genes were not upregulated in RNA-seq and knockdown of *HEXIM1* and *HEXIM2* did not alter their expression (Figure 7C). This suggests that HEXIM1 differential binding stabilizes upregulated mRNAs to maintain their levels.

### Anti-tumorigenic transcripts are stabilized by HEXIM1 binding

To investigate if the HEXIM1 binding shift to mRNA species upregulated by nucleotide stress stabilizes these RNAs, we performed an RNA stability assay where actinomycin D is added to halt the production of new transcripts so that degradation of steady-state transcripts can be observed. We performed this experiment with A771726 treatment and *HEXIM1/HEXIM2* knockdown. We observed that transcripts of *CDKN1A* and *PTEN* undergo a faster rate of degradation with *HEXIM1/HEXIM2* knocked down (Figure 7D). Conversely, the rate of degradation of *CCNT2* mRNA is unchanged (Figure 7D). We performed a complementary RNA stability experiment in the context of *HEXIM1* overexpression in the A375-HEXIM1 cell line. With *HEXIM1* overexpression, *CDKN1A* and *PTEN* transcripts undergo a slower rate of degradation while *CCNT2* remains unchanged (Figure 7E).

Gene ontology analysis of HEXIM1-bound transcripts that were enriched in either the DMSO or A771726 condition revealed that apoptotic transcripts were enriched in nucleotide stress conditions while homeostatic cell maintenance pathways were enriched at steady state (Figure S7D). We propose that differential binding of HEXIM1 to certain transcripts like *CDKN1A* and *PTEN* stabilizes them under nucleotide stress. Other transcripts like *CCNT2* that do not experience differential binding are not affected.

## Discussion

### HEXIM1 is a tumor suppressor in melanoma

Our work establishes a physiological role for HEXIM1 in melanoma *in vivo*, although further genetic validation in a mammalian system is needed. HEXIM1 was discovered as an upregulated gene upon treatment of cells with HMBA (Kusuhara et al., 1999). HMBA induces differentiation in a variety of cancer cell lines and primary human cancer cell cultures (Marks and Rifkind, 1989). HEXIM1 upregulation is correlated with the transition of cancer cells from proliferation to differentiation, and has been studied in breast cancer (Ketchart et al., 2013; Wittmann et al., 2003, 2005; Yeh et al., 2013) and prostate cancer (Mascareno et al., 2012). 7SK snRNP member *LARP7* is mutated in gastric cancer (He et al., 2008; Mori et al., 2002). Rapidly dividing cancer cells are addicted to P-TEFb for proliferative gene expression, where loss of P-TEFb activity leads to growth arrest and apoptosis (Kryštof et al., 2012). This explains the efficacy of anti-cancer agents HMBA, SAHA and JQ1 that modulate HEXIM1 sequestration of PTEFb (Bartholomeeusen et al., 2012). HEXIM1 is an important tumor suppressor that dampens excessive P-TEFb activity in cancer.

The ability for HEXIM1 to respond to cellular stress and participate in a transcriptional transition has great significance in tumorigenesis. Using DHODH inhibitors to create cellular stress by nucleotide starvation upregulates HEXIM1, reducing transcription elongation at genes associated with survival and proliferation. In addition, apoptotic genes upregulated by cellular stress can be stabilized by HEXIM1 binding, reinforcing the shift to a growth suppressive transcriptional state. Metabolic drugs such as lef that induce HEXIM1 can transcriptionally inhibit numerous expressed genes simultaneously, targeting multiple pathways to halt cancer progression. Inducing the *HEXIM1* stress pathway can modulate gene expression through transcription elongation to treat cancer.

Each cell type has an Achilles' heel for stress, and the neural crest is sensitive to low nucleotides, as illustrated by patients with Miller's syndrome with DHOHD mutations and consequent neural crest defects (Ng et al., 2010). Other cell types may be susceptible to different cellular stresses, and respond in a similar manner by activating HEXIM1, reducing productive elongation to help the cell repair or undergo programmed cell death. Finding such dependencies in other cancers could lead to the development of new cancer therapies.

### HEXIM1 couples nucleotide metabolism with transcriptional regulation

When cells are nucleotide starved, transcription is slowed to conserve nucleotides until homeostasis returns. We suggest that one mechanism in which cells conserve nucleotides is to repress transcription elongation, which involves upregulating HEXIM1 to sequester P-TEFb. Increased binding of stress response transcription factor SP1 to the *HEXIM1* promoter upregulates *HEXIM1* in response to nucleotide stress. Newly synthesized HEXIM1 sequesters P-TEFb away from gene promoters, leading to fewer phosphorylated RNA Pol II molecules entering productive elongation. *HEXIM1* expression is tightly linked to nucleotide levels, with decreased nucleotides triggering an increase in *HEXIM1* expression. Cells can take advantage of the transcriptional reprieve, provided by HEXIM1

induced elongation inhibition, until nucleotides return to sufficient levels. HEXIM1 then returns to homeostatic levels, allowing transcription to return to normal. This suggests a feedback mechanism where cells control transcription based on the amount of mRNA precursors available. Cells slow their growth rate via HEXIM1 downregulation of genes associated with proliferation in times of starvation, conserving cellular resources until conditions become favorable.

There are advantages of regulating transcription elongation as a direct consequence of nucleotide starvation or other cellular stresses. Genes in the *Drosophila* embryo involved in key developmental pathways as well as heat shock genes are held in a paused state before induction (Adelman and Lis, 2012). At these genes, transcription has already been initiated as RNA Pol II is recruited to the promoters. RNA Pol II does not immediately transition to a productive elongation phase and instead, remains paused on these promoters before receiving signals to induce productive elongation (Chopra et al., 2009; Muse et al., 2007; Zeitlinger et al., 2007). This poises RNA Pol II at genes that require rapid induction (Adelman and Lis, 2012).

Such a system is highly beneficial to the organism as a quick and concerted response could limit the damage done by the stress. With nucleotide starvation, unfavorable effects might include DNA damage, mis-expression of mRNA and protein, and possibly bioenergetic issues due to the lack of ATP and GTP. An immediate repression of non-essential genes by halting elongation through HEXIM1 sequestration of P-TEFb will allow for stress response genes to be preferentially expressed with the remaining nucleotides available. Inhibiting transcription elongation with nucleotide starvation is a viable mechanism to ensure a quick response to avoid damage from cellular stress. HEXIM1 has been shown to respond to environmental stimuli such as UV light, signaling cascades and transcriptional perturbations by various inhibitors (Peterlin et al., 2012). Our study, together with others, proposes that HEXIM1 is a general stress sensor that responds to cellular stress by modulating gene expression to achieve an appropriate response.

### **HEXIM1 facilitates switching of gene expression programs**

Our study establishes a second function of HEXIM1 of binding mRNAs to promote a gene expression transition. If nucleotide starvation continues at an unsustainable rate, programmed cell death occurs. Apoptotic genes become upregulated as a result and HEXIM1 can bind and stabilize these transcripts, reinforcing apoptotic gene expression. Other than binding 7SK to nucleate the 7SK snRNP and sequester P-TEFb, HEXIM1 can act as a modulator of specific RNA species under different gene expression programs.

The dual functionality of HEXIM1 might explain its importance in differentiation, where HEXIM1 is significantly upregulated (Marks and Rifkind, 1989). During differentiation, proliferation genes are downregulated and genes responsible for downstream cell fate are upregulated. This second function of HEXIM1 could also explain why rapidly dividing cancer cells undergo growth arrest and apoptosis under PTEFb inhibition by drugs. HEXIM1 induction inhibits P-TEFb, similar to treatment with CDK9 inhibitors, to inhibit cancer-associated gene expression. In addition, it stabilizes apoptotic transcripts to promote growth arrest and cell death. The fact that not all HEXIM1 bound transcripts are stabilized

by HEXIM1 suggests the presence of additional factors that are recruited to specific transcripts by unknown mechanisms to aid in HEXIM1-mediated RNA stabilization. HEXIM1 plays an important role in differentiation and tumor suppression by reducing productive elongation of proliferation genes and promoting the expression of cell fate or apoptotic genes respectively, thereby facilitating a transition from one gene expression program to the next.

## Experimental Procedures

### MiniCoopR assay

The miniCoopR vector sequence and construction was previously described (Ceol et al., 2011). MiniCoopR vectors and Tol2 transposase mRNA were microinjected into one-cell zebrafish embryos generated from an incross of Tg(*mitfa*:BRAF(V600E)); *p53*<sup>-/-</sup>; *mitfa*<sup>-/-</sup> zebrafish. Rescued animals were scored weekly for the presence of visible tumors. For *hexim* deletion, the MiniCoopR vector was engineered to express Cas9 under the control of a *mitfa* promoter in order to achieve melanocyte-specific gene targeting. A gRNA efficiently mutating *hexim* was expressed off a *U6* promoter while a gRNA against *p53* was used as a negative control (Ablain et al., 2015). The two vectors were injected into one-cell stage, Tg(*mitfa*:BRAF<sup>V600E</sup>), *p53*<sup>-/-</sup>, *mitfa*<sup>-/-</sup> embryos, and tumor formation was monitored.

### GRO-seq sample preparation and sequencing

GRO-seq was performed as previously described (Kim et al., 2013) with conditions optimized for A375 cells. One million A375 cells were treated with DMSO, 25  $\mu$ M lef, or 25  $\mu$ M A771726. After 48 hr treatment, cells were washed, swelled, and lysed in lysis buffer with IGEPAL detergent. Cells were frozen down, nuclear run-on reaction was performed, and nascent RNA was isolated and sequenced.

### ChIP-seq sample preparation and sequencing

ChIP-seq and ChIP-reChIP were performed as previously described (Batsché et al., 2006; Lee et al., 2006) with conditions optimized for A375 cells. One hundred million A375 cells per condition were treated with DMSO or 25  $\mu$ M A771726. After 48 hr treatment, cells were fixed in formaldehyde and subjected to chromatin immunoprecipitation with HEXIM1, CDK9, POLR2A or SP1 antibodies. For reChIP experiments, eluates were diluted to reduce the SDS concentration before the subsequent immunoprecipitation was performed. 10  $\mu$ L of input DNA and the entire volume of ChIP DNA samples were prepared for sequencing.

### FAST-iCLIP

FAST-iCLIP was performed as described previously (Flynn et al., 2015) with some modifications. A375 cells were cultured and treated with DMSO or 25 $\mu$ M A771726 for 48 hrs, then UV-C crosslinked. Each iCLIP experiment was normalized for total protein amount and partially digested with RNaseI. To isolate HEXIM-bound RNAs, HEXIM1 antibody conjugated to Protein A Dynabeads was incubated with RNaseI-digested lysates overnight at 4°C on rotation. Immunoprecipitation, washing and subsequent biochemical and library preparation steps were carried out for sequencing.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Min Yuan for her help with the metabolomics studies and Dr. Telmo Henriques for his advise on RNA assays. This work was supported by the Howard Hughes Medical Institute and the National Cancer Institute (National Institutes of Health) R01CA103846 (L.I.Z.). L.I.Z. is a founder and stockholder of Fate, Inc., Scholar Rock, and a scientific advisor for Stemgent. J.L.T. is an Agency for Science, Technology & Research, Singapore - National Science Scholarship recipient. C.B.G. is a PhRMA Foundation predoctoral fellow. R.A.Y. is a founder and stockholder of Syros Pharmaceuticals. This work was partially supported by NIH grants 2P01CA120964 (J.M.A.), 5P30CA006516 (J.M.A.), R01CA140485 (T.H.K.) and R21AI107067 (T.H.K.). GRO-seq, ChIP-seq, RNA-seq and FAST-iCLIP sequencing data are deposited in the NCBI Gene Expression Omnibus database with accession number GSE68053.

## References

- Ablain J, Durand EM, Yang S, Zhou Y, Zon LI. A CRISPR/Cas9 Vector System for Tissue-Specific Gene Disruption in Zebrafish. *Dev. Cell.* 2015; 32:756–764. [PubMed: 25752963]
- Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. *Nat. Rev. Genet.* 2012; 13:720–731. [PubMed: 22986266]
- Alazami AM, Al-Owain M, Alzahrani F, Shuaib T, Al-Shamrani H, Al-Falki YH, Alsheddi T, Colak D, Alkuraya FS. Loss of function mutation in LARP7, chaperone of 7SK ncRNA, causes a syndrome of facial dysmorphism, intellectual disability and primordial dwarfism. *Hum. Mutat.* 2012
- Barboric M, Lenasi T, Chen H, Johansen EB, Guo S, Peterlin BM. 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. *Proceedings of the National Academy of Sciences.* 2009; 106:7798–7803.
- Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. *J. Biol. Chem.* 2012; 287:36609–36616. [PubMed: 22952229]
- Batsché E, Yaniv M, Muchardt C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. *Nat. Struct. Mol. Biol.* 2006; 13:22–29. [PubMed: 16341228]
- Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. *Nature.* 2011; 471:513–517. [PubMed: 21430779]
- Chabosseau P, Buhagiar-Labarchède G, Onclercq-Delic R, Lambert S, Debatisse M, Brison O, Amor-Guéret M. Pyrimidine pool imbalance induced by BLM helicase deficiency contributes to genetic instability in Bloom syndrome. *Nat Commun.* 2011; 2:368. [PubMed: 21712816]
- Chang L, Guo R, Huang Q, Yen Y. Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms. *Cell Rep.* 2013; 3:1389–1397. [PubMed: 23643536]
- Chopra VS, Hong J-W, Levine M. Regulation of Hox gene activity by transcriptional elongation in *Drosophila*. *Curr. Biol.* 2009; 19:688–693. [PubMed: 19345103]
- Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA Releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and Activates HIV Transcription. *PLoS Pathog.* 2007; 3
- Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. *J. Biol. Chem.* 1982; 257:2041–2048. [PubMed: 6173384]
- ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature.* 2012; 489:57–74. [PubMed: 22955616]
- Flynn RA, Martin L, Spitale RC, Do BT, Sagan SM, Zarnegar B, Qu K, Khavari PA, Quake SR, Sarnow P, et al. Dissecting noncoding and pathogen RNA-protein interactomes. *RNA.* 2015; 21:135–143. [PubMed: 25411354]

- Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. *Mol. Cell. Biol.* 2004; 24:787–795. [PubMed: 14701750]
- Guo J, Price DH. RNA polymerase II transcription elongation control. *Chem. Rev.* 2013; 113:8583–8603. [PubMed: 23919563]
- He N, Jahchan NS, Hong E, Li Q, Bayfield MA, Maraia RJ, Luo K, Zhou Q. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. *Mol. Cell.* 2008; 29:588–599. [PubMed: 18249148]
- Huang W-Y, Hsu S-D, Huang H-Y, Sun Y-M, Chou C-H, Weng S-L, Huang H-D. MethHC: a database of DNA methylation and gene expression in human cancer. *Nucleic Acids Res.* 2015; 43:D856–D861. [PubMed: 25398901]
- Jeronimo C, Forget D, Bouchard A, Li Q, Chua G, Poitras C, Thérien C, Bergeron D, Bourassa S, Greenblatt J, et al. Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. *Mol. Cell.* 2007; 27:262–274. [PubMed: 17643375]
- Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with *in vivo* tumor rejection. *Proc. Natl. Acad. Sci. U.S.A.* 1994; 91:6458–6462. [PubMed: 8022805]
- Ketchart W, Smith KM, Krupka T, Wittmann BM, Hu Y, Rayman PA, Doughman YQ, Albert JM, Bai X, Finke JH, et al. Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis. *Oncogene.* 2013; 32:3829–3839. [PubMed: 22964639]
- Kim YJ, Greer CB, Cecchini KR, Harris LN, Tuck DP, Kim TH. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. *Oncogene.* 2013; 32:2828–2835. [PubMed: 23435418]
- Kryštof V, Baumli S, Fürst R. Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target. *Curr Pharm Des.* 2012; 18:2883–2890. [PubMed: 22571657]
- Kusuhara M, Nagasaki K, Kimura K, Maass N, Manabe T, Ishikawa S, Aikawa M, Miyazaki K, Yamaguchi K. Cloning of Hexamethylene-Bis-Acetamide-Inducible Transcript, HEXIM1, in Human Vascular Smooth Muscle Cells. *Biomed Res.* 1999; 20:273–279.
- Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. *Nat Protoc.* 2006; 1:729–748. [PubMed: 17406303]
- Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res.* 2008; 68:664–673. [PubMed: 18245465]
- Liu P, Xiang Y, Fujinaga K, Bartholomeeusen K, Nilson KA, Price DH, Peterlin BM. Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein (snRNP) Activates Hexamethylene Bisacetamide-inducible Protein (HEXIM1) Transcription. *J. Biol. Chem.* 2014; 289:9918–9925. [PubMed: 24515107]
- Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW-M, Phang JM. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. *Proc. Natl. Acad. Sci. U.S.A.* 2012; 109:8983–8988. [PubMed: 22615405]
- Marks PA, Rifkind RA. Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells. *Environ. Health Perspect.* 1989; 80:181–188. [PubMed: 2647479]
- Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. *J. Biol. Chem.* 1996; 271:27176–27183. [PubMed: 8900211]
- Mascareno EJ, Belashov I, Siddiqui MAQ, Liu F, Dhar-Mascareno M. Hexim-1 modulates androgen receptor and the TGF- $\beta$  signaling during the progression of prostate cancer. *Prostate.* 2012; 72:1035–1044. [PubMed: 22095517]

- McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. *Cancer Res.* 1990; 50:3545–3550. [PubMed: 2187598]
- Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. *Exp. Cell Res.* 1989; 181:305–316. [PubMed: 2647496]
- Mori Y, Sato F, Selaru FM, Oлару A, Perry K, Kimos MC, Tamura G, Matsubara N, Wang S, Xu Y, et al. Instability typing reveals unique mutational spectra in microsatellite-unstable gastric cancers. *Cancer Res.* 2002; 62:3641–3645. [PubMed: 12097267]
- Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, Grissom SF, Zeitlinger J, Adelman K. RNA polymerase is poised for activation across the genome. *Nat. Genet.* 2007; 39:1507–1511. [PubMed: 17994021]
- Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, et al. Exome sequencing identifies the cause of a mendelian disorder. *Nat. Genet.* 2010; 42:30–35. [PubMed: 19915526]
- Peterlin BM, Brogie JE, Price DH. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. *Wiley Interdiscip Rev RNA.* 2012; 3:92–103. [PubMed: 21853533]
- Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. c-Myc regulates transcriptional pause release. *Cell.* 2010; 141:432–445. [PubMed: 20434984]
- Raskin L, Fullen DR, Giordano TJ, Thomas DG, Frohm ML, Cha KB, Ahn J, Mukherjee B, Johnson TM, Gruber SB. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. *J. Invest. Dermatol.* 2013; 133:2585–2592. [PubMed: 23633021]
- Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia.* 2004; 6:1–6. [PubMed: 15068665]
- Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. *J. Neurosci.* 2003; 23:3597–3606. [PubMed: 12736330]
- Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. *Clin. Cancer Res.* 2005; 11:7234–7242. [PubMed: 16243793]
- Weinberg G, Ullman B, Martin DW. Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools. *Proc. Natl. Acad. Sci. U.S.A.* 1981; 78:2447–2451. [PubMed: 7017732]
- White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson Matthew L, Mosher J, Kaufman C, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. *Nature.* 2011; 471:518–522. [PubMed: 21430780]
- Wittmann BM, Wang N, Montano MM. Identification of a Novel Inhibitor of Breast Cell Growth That Is Down-Regulated by Estrogens and Decreased in Breast Tumors. *Cancer Res.* 2003; 63:5151–5158. [PubMed: 12941847]
- Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. *Oncogene.* 2005; 24:5576–5588. [PubMed: 15940264]
- Yamada T, Yamaguchi Y, Inukai N, Okamoto S, Mura T, Handa H. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. *Mol. Cell.* 2006; 21:227–237. [PubMed: 16427012]
- Yeh I-J, Ogba N, Bensigner H, Welford SM, Montano MM. HEXIM1 down-regulates hypoxia-inducible factor-1 $\alpha$  protein stability. *Biochem. J.* 2013; 456:195–204. [PubMed: 24015760]
- Yik JHN, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. *Mol. Cell.* 2003; 12:971–982. [PubMed: 14580347]

Zeitlinger J, Stark A, Kellis M, Hong J-W, Nechaev S, Adelman K, Levine M, Young RA. RNA polymerase stalling at developmental control genes in the *Drosophila melanogaster* embryo. *Nat. Genet.* 2007; 39:1512–1516. [PubMed: 17994019]

Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. *Cell.* 2012; 148:259–272. [PubMed: 22225612]

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**Highlights**

- HEXIM1 is a tumor suppressor in melanoma that responds to nucleotide stress.
- In nucleotide stress, HEXIM1 sequesters P-TEFb to inhibit oncogenic transcription.
- HEXIM1 binds and stabilizes anti-tumorigenic transcripts under nucleotide stress.



**Figure 1. *HEXIM1* is downregulated in melanoma**

(A) Gene expression plot of *HEXIM1* microarray data from Talantov et al. comparing nevi/tumor samples versus normal skin controls. The data is represented as mean  $\pm$  standard deviation (SD).

(B) Gene expression plot of *HEXIM1* microarray data from Lin et al. comparing primary melanoma cultures and melanoma cell lines to melanocyte culture controls (mean  $\pm$  SD).


(C) Bar graph of H-scores for normal epidermis, nevi and melanoma samples (mean  $\pm$  SD).

(D) *HEXIM1* locus methylation plot from TCGA skin cutaneous melanoma samples, analyzed by MethHC (mean  $\pm$  SD).

(E) Real time RT-PCR for *HEXIM1* expression in A375 cells treated with 5-azacytidine for 24 hrs normalized to *GAPDH* (mean of 3 replicates  $\pm$  SD).

(F) Cell number of A375 cells treated with 5-azacytidine for 24-72 hrs relative to DMSO controls (mean of 3 replicates  $\pm$  SD).

See also Figure S1.



**Figure 2. *HEXIM1* activity suppresses melanoma *in vivo***

(A) 19 week old *Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>* zebrafish with rescued melanocytes expressing tumor accelerator *SETDB1*, background control *EGFP* or *HEXIM1/hexim1* in the MiniCoopR system.


(B) Tumor-free survival curves for *EGFP*, *SETDB1* and *HEXIM1/hexim1* MiniCoopR zebrafish over 25 weeks. Percentages of the total number of zebrafish that were tumor-free each week are plotted.

(C) Tumor-free survival curves for MiniCoopR overexpression of human *HEXIM1-4A*, and *HEXIM1-4D*.

(D) Tumor-free survival curves for MiniCoopR expression of *p53* and *hexim* CRISPRs.

(E) Tumor growth rates of individual mouse xenografts with a Tet-On *HEXIM1*-inducible A375 cell line (A375-*HEXIM1*) over 14 days. Mice were fed either a standard diet or doxycycline diet (mean of 7 replicates ± SD).

See also Figure S2.



**Figure 3. Knockdown of *HEXIM1* rescues nucleotide stress-associated neural crest ablation and melanoma suppression phenotypes**


(A) Zebrafish embryos were injected with 8 ng of *hexim1* or control morpholino (MO), or a combination of *hexim1* MO and 300 pg of human *HEXIM1* mRNA. Embryos were treated with DMSO or 6.5  $\mu$ M lef at 50% epiboly and *in situ* hybridization was performed at 24 hours post fertilization (hpf) for *crestin* or *mitfa* expression. Dorsal views of embryos are shown. Numbers indicate the number of embryos with the shown phenotype vs. the total number of embryos in the clutch.

(B) Embryos treated as in (A) were scored for melanocytes at 2 dpf.

(C) Four clutches of embryos were analyzed for rescue of melanocytes under the conditions of uninjected, *hexim1* MO injected, lef treatment or *hexim1* MO injected with lef treatment. Percentages of the number of embryos rescued in each clutch are plotted (mean  $\pm$  SD).

(D) Cell number of A375 cells treated with 25  $\mu$ M A771726 in combination with siRNA pools for *GAPDH*, *HEXIM1* and *HEXIM2* relative to DMSO controls (mean of 3 replicates  $\pm$  SD).

See also Figure S3.



**Figure 4. *HEXIM1* is upregulated by pyrimidine nucleotide stress**

(A) Real time RT-PCR for *hexim1* expression in 24 hpf zebrafish embryos treated with lef normalized to *gapdh* (mean of 3 replicates  $\pm$  SD).

(B) Real time RT-PCR for *HEXIM1* expression in A375 cells treated with A771726 for 72 hrs normalized to *GAPDH* (mean of 3 replicates  $\pm$  SD).

(C) Western blot for *hexim1* in 24 hpf zebrafish embryos treated with lef from 50% epiboly to 24 hpf. Numbers represent quantified pixel density of *hexim1* bands relative to DMSO control.

(D) Western blot for *HEXIM1* in A375 cells treated with A771726 for 72 hrs with quantified *HEXIM1* pixel density relative to the DMSO control.


(E) *HEXIM1*-luciferase reporter assay in A375 cells treated with 10 mM HMBA, DMSO or 25  $\mu$ M A771726 for 48 hrs (mean of 2 replicates  $\pm$  SD).

(F) Western blot of *HEXIM1* and TATA-binding protein (TBP) in A375 cells treated with 25  $\mu$ M A771726 for 1, 24, 48 and 72 hrs with quantified *HEXIM1* pixel density relative to DMSO control.

(G) Quantification of cell number of A375 cells treated like in (F) (mean of 3 replicates  $\pm$  SD).

(H) Real time RT-PCR for *HEXIM1* expression in A375 cells treated with 25  $\mu$ M A771726, a cocktail of 10  $\mu$ g/mL pyrimidine nucleotides (UMP and CMP) and a combination of both A771726 and nucleotides at 24 and 72 hrs normalized to *GAPDH* (mean of 3 replicates  $\pm$  SD).

See also Figure S4 and Table S1.




**Figure 5. *HEXIM1* is upregulated under nucleotide stress by SP1**

(A) Real time RT-PCR for *HEXIM1* expression in A375 cells treated with 25  $\mu$ M A771726 and pooled siRNAs for non-targeting siRNAs, *GAPDH* and *SP1* at 48 hrs normalized to *ACTB* (mean of 3 replicates  $\pm$  SD). This is a subset of the full screening data in Figure S5A.

(B) Cell number of A375 cells treated with 25  $\mu$ M A771726 in combination with a non-targeting siRNA pool, an *SP1* or *HEXIM1* siRNA pool for gene knockdown relative to DMSO controls (mean of 3 replicates  $\pm$  SD).

(C) SP1 ChIP-seq peaks around the *HEXIM1* locus in A375 cells treated with DMSO or A771726. Read density at the *HEXIM1* locus is normalized to all called peaks and quantified.

See also Figure S5.



**Figure 6. HEXIM1 reduces productive elongation at tumorigenic genes by P-TEFb sequestration under nucleotide stress**

(A) Metagenesis analysis of all transcribed genes  $\pm$  2 kb around transcription units for CDK9 binding regions in DMSO- or A771726-treated (25  $\mu$ M for 48 hrs) A375 cells.

(B) Metagenesis analysis of all transcribed genes  $\pm$  2 kb around transcription units for HEXIM1 binding regions in DMSO- or A771726-treated (25  $\mu$ M for 48 hrs) A375 cells.


(C) ChIP-seq region plots representing the distribution of regions bound by CDK9 and HEXIM1 in A375 cells, treated with either DMSO or 25  $\mu$ M A771726 for 48 hrs,  $\pm$  2.5 kb relative to all CDK9 or HEXIM1 bound sites in the DMSO-treated A375 cells.

(D) RNA Pol II traveling ratios (TR) from GRO-seq performed on 48 hr DMSO (white), 25  $\mu$ M lef (blue) or 25  $\mu$ M A771762 (red) treated A375 cells (mean of 2 replicates  $\pm$  SD).

(E) Metagenesis analysis of RNA Pol II occupancy  $\pm$  2 kb around transcription units from GRO-seq described in (D).

(F) Venn diagram of genes in the lef (blue) or A771762 (red) treated condition which have an RNA Pol II TR fold change of > 1.3.

See also Figure S6 and Table S2.



**Figure 7. HEXIM1 binds and maintains levels of anti-tumorigenic transcripts under nucleotide stress**

(A) Pie charts summarizing the switch in mRNAs bound by HEXIM1 in response to nucleotide depletion.

(B) FAST-iCLIP RT-stops representing regions of HEXIM1 binding mapped to three representative genes.

(C) Real time RT-PCR on A375 cells treated with 25  $\mu$ M A771726 and a combination of *HEXIM1* and *HEXIM2* pooled siRNAs to examine expression in three genes upregulated by nucleotide depletion and increasingly bound by HEXIM1 (*CDKN1A*, *PTEN* and *SLC5A3*), and two genes unchanged by nucleotide depletion and with no change in HEXIM1 binding (*CCNT2* and *DCBLD2*) (mean of 3 replicates  $\pm$  SD). Data is normalized to *RPL11*.

(D) RNA stability assay where A375 were first treated with either 25  $\mu$ M A771726 or 25  $\mu$ M A771726 in combination with siRNA knockdown of *HEXIM1* and *HEXIM2* for 48 hrs, followed by 5  $\mu$ g/mL actinomycin D treatment. RNA was isolated at various time points

after actinomycin D treatment and relative mRNA abundance over time is plotted for *CDKN1A*, *PTEN* and *CCNT2* (mean of 3 replicates  $\pm$  SD). Data is normalized to *RPL11*. (E) The RNA stability assay in (D) was repeated with the A375-HEXIM1 cell line treated with DMSO or 1  $\mu$ g/ml doxycycline to induce HEXIM1 expression for 24 hrs (mean of 3 replicates  $\pm$  SD).

See also Figure S7 and Table S3.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript